NASDAQ · CMND
Clearmind Medicine financials
$0.8114+3.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Oct 31 | FY24 Oct 31 | FY23 Oct 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$5.7M | -$5.8M | -$6.3M |
| Net income | -$3.9M | -$5.3M | -$8.6M |
| Net margin | — | — | — |
| Diluted EPS | $-303.50 | $-678.00 | $-17030.40 |
| EBITDA | -$5.7M | -$5.8M | -$6.3M |
| Operating cash flow | -$4.7M | -$4.9M | -$6.3M |
| Free cash flow | -$4.7M | -$4.9M | -$6.3M |
| Diluted shares | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Oct 31 | Oct 31 | Oct 31 |
|---|---|---|---|
| Cash & equivalents | $3.9M | $6.6M | $5.4M |
| Short-term investments | $1.7M | $289.4K | $86.1K |
| Total debt | $1.8M | $0.00 | $0.00 |
| Total assets | $6.1M | $7.3M | $6.0M |
| Total liabilities | $4.9M | $4.1M | $5.0M |
| Shareholders' equity | $1.2M | $3.1M | $983.5K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology